Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-002243
Filing Date
2025-05-12
Accepted
2025-05-12 09:05:13
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10592
2 AMYLYX PHARMACEUTICALS, INC. p25-1021exhibit99_1.htm EX-99.1 3544
  Complete submission text file 0000902664-25-002243.txt   15786
Mailing Address 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116
Business Address 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116 617-867-2800
Adage Capital Management, L.P. (Filed by) CIK: 0001535978 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Subject) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-93265 | Film No.: 25932863
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)